Quarterly Results, page-4

Spoke to company secretary share of market is still stable at 13.50 to 14 % - Acrux is a buy also I think the FDA report will be in favour of ACR . It has been a year jan 2014 since their initial warning came out - if they were that concerned they would have come out with something much earlier . Also 12% of the stock has still been shorted - this is $20m that needs to be purchased back , shorters will be squeezed , also the exchange rate is in favour of ACR it has gone from ,875 to about ,80 from 3q 2014 to Dec 2014
This will add abt $6m fx gains to bottom line .
Dividends are taxed free and franked - just buy buy buy !!!!